FDA Commissioner Margaret Hamburg talks about her experience as Commissioner of the FDA.
Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.
Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP
Friends of Cancer Research's 2014 Annual Report is now available for download.
The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.
Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing
Xalkori (crizotinib) - (Pfizer)
for the treatment of ROS1-positive non-small cell lung cancer (NSCLC)
Viaskin Peanut - (DBV)
for the treatment of peanut allergy in children
Grazoprevir/Elbasvir - (Merck)
for the treatment of hepatitis C genotype 4
FDA Commissioner Dr. Margaret Hamburg discussed her experience working with the FDA.
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700